About Taris Biomedical
Taris Biomedical is a company based in Lexington (United States) founded in 2008 by Robert Langer was acquired by Johnson & Johnson in December 2019. Taris Biomedical has raised $108.87 million across 6 funding rounds from investors including Johnson & Johnson, Flagship Pioneering and RA Capital. Taris Biomedical operates in a competitive market with competitors including Alessa Therapeutics and Vensica Medical, among others.
- Headquarter Lexington, United States
- Founders Robert Langer
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Taris Biomedical Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$108.87 M (USD)
in 6 rounds
-
Latest Funding Round
$25 M (USD), Series B
Dec 21, 2017
-
Investors
Johnson & Johnson
& 8 more
-
Employee Count
Not available
-
Acquired by
Johnson & Johnson
(Dec 20, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Taris Biomedical
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Taris Biomedical
Taris Biomedical has successfully raised a total of $108.87M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $25 million completed in December 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Taris Biomedical
Taris Biomedical has secured backing from 9 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Johnson & Johnson, Flagship Pioneering and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Life sciences-focused venture capital firm
|
Locked | Locked | Locked | |
|
US focused venture capital firm
|
Locked | Locked | Locked |
Investor details for Taris Biomedical
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Taris Biomedical
Investment portfolio details for Taris Biomedical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Taris Biomedical
Detailed financials for Taris Biomedical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Taris Biomedical Comparisons
Peer comparison for Taris Biomedical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Taris Biomedical
Taris Biomedical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alessa Therapeutics and Vensica Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Sustained drug delivery implants for prostate tumors are developed.
|
|
| Locked | Locked | Locked |
Catheters for ultrasound-guided drug delivery to the bladder are developed.
|
Detailed competitors of Taris Biomedical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Taris Biomedical
Complete news archive for Taris Biomedical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Taris Biomedical
Taris Biomedical was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Taris Biomedical is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Taris Biomedical is a funded company, having raised a total of $108.87M across 6 funding rounds to date.
TARIS Biomedical has developed drug delivery technology for the local sustained delivery of therapeutics to the genitourinary system. Its first program, LiRIS (lidocaine releasing intravesical system), for the treatment of interstitial cystitisbladder pain syndrome was acquired by Allergan in Aug 2014. Currently developing a broad portfolio of products for several bladder diseases, including bladder cancer and overactive bladder. MIT start-up, backed by Polaris, Flagship, Flybridge and Third Rock Ventures.
Taris Biomedical's top competitors include Vensica Medical and Alessa Therapeutics.
Taris Biomedical has 9 investors. Key investors include Johnson & Johnson, Flagship Pioneering, RA Capital, Bristol-Myers Squibb, and Yonghua Capital.